Maravai LifeSciences Holdings, Inc. (MRVI) Q1 FY26 Earnings Call

Strong Q1 execution drove higher 2026 guidance, but second-half Tri Link growth is expected to moderate [32][175].

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length41 minutes
EPS$-0.03
EPS consensus$-0.07
Revenue$65.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All MRVI earnings ยท Back to MRVI overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.